ATE58473T1 - Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe. - Google Patents

Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe.

Info

Publication number
ATE58473T1
ATE58473T1 AT87305086T AT87305086T ATE58473T1 AT E58473 T1 ATE58473 T1 AT E58473T1 AT 87305086 T AT87305086 T AT 87305086T AT 87305086 T AT87305086 T AT 87305086T AT E58473 T1 ATE58473 T1 AT E58473T1
Authority
AT
Austria
Prior art keywords
levodopa
carbidopa
delayed
controlled release
release carbidopa
Prior art date
Application number
AT87305086T
Other languages
German (de)
English (en)
Inventor
Robert E Dempski
Donald W Nibbelink
Edward C Scholtz
Scott A Reines
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25365017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE58473(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE58473T1 publication Critical patent/ATE58473T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT87305086T 1986-06-16 1987-06-09 Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe. ATE58473T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87498886A 1986-06-16 1986-06-16
EP87305086A EP0253490B1 (en) 1986-06-16 1987-06-09 Controlled release combination of carbidopa/levodopa

Publications (1)

Publication Number Publication Date
ATE58473T1 true ATE58473T1 (de) 1990-12-15

Family

ID=25365017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87305086T ATE58473T1 (de) 1986-06-16 1987-06-09 Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe.

Country Status (17)

Country Link
EP (1) EP0253490B1 (enExample)
JP (1) JPS6354319A (enExample)
KR (1) KR950002882B1 (enExample)
AT (1) ATE58473T1 (enExample)
AU (1) AU597670B2 (enExample)
CY (1) CY1578A (enExample)
DE (1) DE3766308D1 (enExample)
DK (1) DK170514B1 (enExample)
ES (1) ES2018548B3 (enExample)
GR (1) GR3001102T3 (enExample)
HK (1) HK56191A (enExample)
IE (1) IE60508B1 (enExample)
IL (1) IL82823A (enExample)
NZ (1) NZ220599A (enExample)
PT (1) PT85049B (enExample)
SG (1) SG52191G (enExample)
ZA (1) ZA874233B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US5095054A (en) * 1988-02-03 1992-03-10 Warner-Lambert Company Polymer compositions containing destructurized starch
IL94588A0 (en) * 1989-06-22 1991-04-15 Warner Lambert Co Polymer base blend compositions containing destructurized starch
CA2037178A1 (en) * 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
HU208495B (en) * 1990-06-27 1993-11-29 Alkaloida Vegyeszeti Gyar Process for producing retarde pharmaceutical compositions
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5624960A (en) * 1991-01-23 1997-04-29 Isis Pharma Gmbh Orally administrable drugs for the treatment of central dopamine deficiency conditions
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
DE4341156C2 (de) * 1993-12-02 1997-11-13 Wacker Chemie Gmbh Verwendung von in Wasser redispergierbaren Kunststoffdispersionspulvern als Arzneimittelträger
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US5945424A (en) * 1998-07-31 1999-08-31 G & H Associates, Inc. Treatment of periodic limb movement syndrome
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
PT1751087E (pt) * 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
WO2007055329A1 (ja) 2005-11-11 2007-05-18 Asahi Kasei Chemicals Corporation 徐放性固形製剤
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
CN101910113A (zh) 2007-12-28 2010-12-08 怡百克制药公司 左旋多巴控释制剂及其用途
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
HK1211836A1 (en) * 2013-03-28 2016-06-03 Omniactive Health Technologies Limited Neuroprotective effect of carotenoids in brain
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
ES2823000T3 (es) 2013-10-07 2021-05-05 Impax Laboratories Llc Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas
WO2015127558A1 (en) * 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
JP2024501235A (ja) 2020-12-22 2024-01-11 アムニール ファーマスーティカルズ エルエルシー レボドパ投薬レジメン
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH468192A (de) * 1964-06-19 1969-02-15 Ciba Geigy Verfahren zur Herstellung von Arzneimitteln in Perlenform
US3632739A (en) * 1969-12-29 1972-01-04 Sandoz Ag Solid sustained release pharmaceutical preparation
EP0082880B1 (en) * 1981-07-08 1986-06-11 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
DK302587A (da) 1987-12-17
IE60508B1 (en) 1994-07-27
AU7422887A (en) 1987-12-17
PT85049B (pt) 1990-03-08
AU597670B2 (en) 1990-06-07
ZA874233B (en) 1987-12-14
SG52191G (en) 1991-08-23
IE871559L (en) 1987-12-16
CY1578A (en) 1991-12-20
IL82823A (en) 1991-03-10
HK56191A (en) 1991-07-26
EP0253490B1 (en) 1990-11-22
KR880000086A (ko) 1988-03-23
DE3766308D1 (de) 1991-01-03
IL82823A0 (en) 1987-12-20
GR3001102T3 (en) 1992-05-12
PT85049A (en) 1987-07-01
DK302587D0 (da) 1987-06-15
DK170514B1 (da) 1995-10-09
KR950002882B1 (ko) 1995-03-28
NZ220599A (en) 1990-10-26
ES2018548B3 (es) 1991-04-16
JPS6354319A (ja) 1988-03-08
JPH0445B2 (enExample) 1992-01-06
EP0253490A1 (en) 1988-01-20

Similar Documents

Publication Publication Date Title
ATE58473T1 (de) Kombination von carbidopa/levodopa mit verzoegerter wirkstoffabgabe.
DE3875705D1 (de) Carbidopa-levodopa-zusammensetzung mit gesteuerter freigabe.
ATE77962T1 (de) Dosierungssystem fuer transdermale absorption von arzneimittelwirkstoffen.
NO951592D0 (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
ATE89755T1 (de) Vorrichtung zur transdermalen applikation von medikamenten.
ATE49126T1 (de) Mittel zur transdermalen applikation von arzneistoffen.
ES2039437T3 (es) Liberacion controlada de polipeptidos macromoleculares.
DK0388306T3 (da) Farmaceutisk præparat til behandling af smerte knyttet til herpes zoster og postherpetisk neuralgi ved topisk påføring af l
DE3879853D1 (de) Klebstoffzusammensetzung, zusammensetzung mit kontrollierter wirkstofffreisetzung und system zur transdermalen anwendung von arzneien.
DE3687458D1 (de) Filmbildende arzneimitteltraeger zur verabreichung von arzneimitteln an naegeln
ATE81285T1 (de) Freisetzungssysteme fuer die kontrollierte anwendung von lhrh-analoga.
FI104151B1 (fi) Laite vaikuttavan aineen luovuttamiseksi ohjatusti
DK0612519T3 (da) Anvendelse af et calciumpræparat i et medikament til terapeutisk anvendelse på malkekøer, der lider af hypocalcaemia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time